Dynavax TechnologiesDVAX
About: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Employees: 408
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
171% more call options, than puts
Call options by funds: $6.23M | Put options by funds: $2.3M
38% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 32
5% more funds holding
Funds holding: 238 [Q2] → 250 (+12) [Q3]
5% less capital invested
Capital invested by funds: $1.52B [Q2] → $1.44B (-$74.2M) [Q3]
4.22% less ownership
Funds ownership: 103.2% [Q2] → 98.98% (-4.22%) [Q3]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q2] → 4 (-1) [Q3]
20% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 90
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Edward White 24% 1-year accuracy 33 / 140 met price target | 126%upside $29 | Buy Reiterated | 8 Nov 2024 |
Financial journalist opinion
